It’s the flu again.

Pandemic influenza (the flu) is an acute respiratory disease caused by influenza viruses. Among the population, influenza A and B viruses are seasonally prevalent every year and enter the flu season throughout the country from October to April of each year. About 20-30 per cent of children are sick, most of them are mild and can improve on their own. However, the number of cases of serious illness and death is not small every year. Because of the variability of influenza viruses, influenza vaccines are not 100 per cent preventable, but they are also necessary for children with less physical resistance (over six months). In vitro influenza viruses are sensitive to common disinfectants such as ethanol, iodine volts and iodium, UV and heat, and can be eliminated by 30min below 56°C. Through its tissue and respiratory mucous membranes, the virus combines with saliva receptors, 8h completing a reproduction cycle and producing a large number of generational particles of the virus; it spreads through the mucous membranes of the respiratory tract and infects other cells, leading to the mutation, necrosis and even decomposition of the host cell, resulting in an increase in the mucous membranes, edema and secretions, leading to signs of respiratory infections; some of the viruses and their metabolites enter the blood, resulting in viral haemoemia; and the induction of cell-induced storms, leading to a full-body inflammation response, as well as to the failure of ARDS, shock and polyvulators. In children, pneumonia is the most common complication of influenza and can be classified as primary influenza viral pneumonia, secondary bacterial pneumonia or hybrid pneumonia. In the central nervous system, encephalitis, meningitis, acute degenerative encephalitis, polio, Gillan-Barre syndrome, etc. In addition to heart, which can lead to cardiac inflammation, cardiovascular enzyme rise, electrocardial abnormalities, and heart failure in cases of serious diseases, there will be aerobic pain, muscle incompetence, hepatic enzymes, kidney failure, serostatase, rise in myoglobin, acute kidney damage, etc. In the case of flu seasons, the following symptoms should be taken into account: a healthy child in a normal state of health: a sudden fever with a temperature of 39-40°C, with a cold, a cold war, a headache in the whole body, severe muscle pain, extreme fatigue and abscess, often coughing, anal pain, aldicarb or nostrils, with a small amount of nausea, vomiting, diarrhoea, and a child with digestive symptoms. Clinical symptoms of infant and young child influenza are often unusual. Neonatal influenza is rare, but is prone to combined pneumonia, often manifested in sepsis, such as sleeping addiction, non-weaning, breathing pauses, etc. In addition to this, there is a need to be alert to the heavy influenza infection, which can last longer than 39°C if it is rapidly developing; to pneumonia, respiratory difficulties and persistent hypoxic haemorrhage in 5-7d; and to rapid progress towards acute respiratory distress syndrome (ARDS), sepsis, infectious shock, heart failure, cardiac arrest, kidney failure and even multiple organ functional disorders. The combination of bacterial infections increases influenza mortality. Clinically diagnosed and confirmed cases should be treated in isolation as early as possible; antiviral treatment should be provided as early as possible; and empirical anti-influenza virus treatment should be provided as early as possible for cases of influenza that have a high risk of serious or serious influenza; and anti-influenza treatment within 48h of a disease can reduce complications, reduce disease mortality and reduce hospitalization times. Even for serious cases with more than 48h, the early application of antiviral drugs is recommended; the main drugs currently treated and with low resistance are: Ostawe (prematures use less than a full month; birthmarks less than 38 weeks, dosages of 1.0 mg/kg per second, Bid; infants of 38-40 weeks of age, 1.50 mg/kg per second, Bid; infants of 40 weeks of age above 3 mg/kg per second, Bid; prevention: 3 mg/kg per second, qd); 10 mg in Zanamwe (two inhalations, Bid, 12h)